https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-02-08 / Crit. Rev. Oncol. Hematol. 2008 May;66(2):118-34
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-02-08 / Crit. Rev. Oncol. Hematol. 2008 May;66(2):118-342008-02-08 00:00:002019-02-15 08:49:32Dendritic cell vaccines in melanoma: from promise to proof?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-02-01 / Expert Rev Anticancer Ther 2008 Feb;8(2):243-57
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-02-01 / Expert Rev Anticancer Ther 2008 Feb;8(2):243-572008-02-01 00:00:002019-02-15 08:52:23Immunotherapy opportunities in ovarian cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-02-01 / Horm. Metab. Res. 2008 Feb;40(2):108-16
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-02-01 / Horm. Metab. Res. 2008 Feb;40(2):108-162008-02-01 00:00:002019-02-15 08:53:23Dendritic cell vaccination induces tumor epitope-specific Th1 immune response in medullary thyroid carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-01-01 / Cancer Ther 2008;6(B):955-964
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-01-01 / Cancer Ther 2008;6(B):955-9642008-01-01 00:00:002019-02-15 08:52:42A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-01-01 / Rev Recent Clin Trials 2008 Jan;3(1):10-21
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-01-01 / Rev Recent Clin Trials 2008 Jan;3(1):10-212008-01-01 00:00:002019-02-15 08:46:52Dendritic cell immunotherapy for malignant gliomas
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-01-01 / Methods Mol. Biol. 2008;423:139-53
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-01-01 / Methods Mol. Biol. 2008;423:139-532008-01-01 00:00:002019-02-15 08:48:15Delivery of whole tumor lysate into dendritic cells for cancer vaccination
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-12-21 / J. Leukoc. Biol. 2008 Mar;83(3):742-54
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-12-21 / J. Leukoc. Biol. 2008 Mar;83(3):742-542007-12-21 00:00:002019-02-15 08:44:35Copulsing tumor antigen-pulsed dendritic cells with zoledronate efficiently enhance the expansion of tumor antigen-specific CD8+ T cells via Vgamma9gammadelta T cell activation
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-12-05 / J Virol 2008 Feb;82(4):1968-79
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-12-05 / J Virol 2008 Feb;82(4):1968-792007-12-05 00:00:002023-01-23 10:33:37Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-11-01 / Zhejiang Da Xue Xue Bao Yi Xue Ban 2007 Nov;36(6):592-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-11-01 / Zhejiang Da Xue Xue Bao Yi Xue Ban 2007 Nov;36(6):592-72007-11-01 00:00:002019-02-15 08:46:53[Dendritic cells pulsed with glioma RNA induce immunity against intracranial gliomas]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-11-01 / Br. J. Haematol. 2007 Nov;139(3):415-24
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-11-01 / Br. J. Haematol. 2007 Nov;139(3):415-242007-11-01 00:00:002019-02-15 08:51:00Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides
